A Single-center Study Of Imatinib In The Treatment Of Chronic Myeloid Leukemia

Objective:To summarize the efficacy and survival of imatinib as the first choice for patients with single center chronic myelocytic leukemia.Method:A retrospective analysis from January 2007 to January 2017,192 cases of newly diagnosed CML patients,including 174 cases of CP,18 cases of AP,according to the Sokal score each stage respectively,96 cases,59cases,19cases,according to the classification,staging,tolerance and compliance will be adjusted appropriately imatinib dose,300mg/D-600mg/D analysis of curative effect,drug resistance and survival.Result:Imatinib therapy for chronic myeloid leukemia in chronic phase,accelerated period of 3M were the best reaction condition were 131 cases,10 cases(0.092%,P>0.05),6M was the best reaction condition were 128 cases,8 cases(0.014%,P<0.05),12M was the best reaction condition were 122 cases,6 cases(0.003%,P<0.05);each period survival time(OS5 0.046%,P<0.05)and progression free survival time(PFS,0.042%,P<0.05).According to the Sokal score each stage were the best reaction condition respectively 3M were 80 cases,39 cases,12 cases(0.056,P>0.05),6M were 80 cases,39 cases,9 cases(0.004,P<0.05),12M were 75 cases,37 cases,10 cases(0.056,P>0.098),each period survival time(OS,0.010%,P<0.05)and progression free survival time(PFS,0.005%,P<0.05),All above that chronic phase was better than of accelerated phase.There were 13 adverse drug reactions in 117 patients,which were mainly leukocyte and thrombocytopenia.Conclusion:Imatinib can still be the first choice for patients with CML chronic phase.The resistance gene was detected and the drug was adjusted in a timely manner.